Nanjing Biopharmaceutical Valley Holds International Summit Forum on Research and Development of Viral Tumors and New Drugs

meet the brainstorming to promote the development of new drugs Nanjing Biomedicine Valley held the International Viral Tumor and New Drug Research and Development Summit Forum According to relevant data, according to relevant data, malignant tumors have become the first killer of all kinds of diseases endangering the lives of our residents, for the development of cancer pathology travel effective new drugs is imperative On September 20, the first Nanjing Biopharmaceutical Development Forum and the International Viral Oncology and New Drug Research and Development Summit Forum was held in Nanjing Biomedicine Valley at the foot of the scenic Longwang Mountain Vice Mayor Hua Jing attended the forum.　　Forum site "starlight", "thousand-person plan" special professor - Dr Luo Guangxiang, the National Academy of Sciences, Louise T Zhou, Professor Of the UAB School of Pharmacy and Center for AIDS Research in Biochemistry and Molecular Genetics Sixteen of the industry's top "masters" were gathered, including Professor R Brooke and Dr Jim Wu, CEO of Ark Biocience Inc More than 20% of the different types of cancer are clinically caused by the virus, and more than 80% of liver cancer is caused by HBV and HCV In general, tumor viruses cause cancer through a variety of mechanisms, including undermining the genetic and epigenetic integrity of the host and the balance of the body, interfering with the cellular DNA repair mechanism leading to instability of the genome and mutation of anti-cancer genes, and inactivation of normal cellular signaling pathways However, little is known about the importance of specific cell genes and the role of potential molecular mechanisms and signaling pathways in the occurrence of viral tumors At present, new drugs for the treatment of various cancers are being developed, the Forum has set up a platform to promote exchanges and cooperation, experts in this field to promote the development of new anti-tumor drugs advice.　　Hua Jing said that the city currently has a total of more than 400 pharmaceutical production enterprises, medical device manufacturers, pharmaceutical research and development enterprises, the annual output value of more than 30 billion yuan Among them, Nanjing Biopharmaceutical Valley has gathered more than 180 biopharmaceutical enterprises, becoming the province's most powerful biomedical research and development and incubation strength, one of the most concentrated regions HuaJing said, and strive to make Nanjing Biopharmaceutical Valley into a national innovation of Chinese medicine, chemical major innovation, biopharmaceutical and medical device research and development industrialization base and modern pharmaceutical logistics center with great impact.　　The forum was attended by more than 100 representatives of the Deputy Secretary-General of the Municipal Government, Fang Fang, Deputy Director of the Bureau of Commerce, Wang Lei, Director of the Nanjing High-tech District Management Committee, and Xu Yangwen, Deputy Director of the National High-tech District Management Committee, speech experts, returning biopharmaceutical entrepreneurs, overseas leading talents who have plans to return home to start their own businesses, and representatives of well-known biopharmaceutical enterprises and investment institutions at home and abroad.